Efficacy of Probucol on cognitive function in Alzheimers disease: Study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA Study)

Preclinical, clinical and epidemiological studies support the hypothesis that aberrant systemic metabolism of amyloid-beta (A{beta}) in the peripheral circulation is causally related to the development of Alzheimers disease (AD). Specifically, recent studies suggest that increased plasma concentrations of lipoprotein-A{beta} compromises the brain microvasculature, resulting in extravasation and retention of the lipoprotein-A{beta} moiety. The latter results in an inflammatory response and neurodegeneration ensues. Probucol, a historic cholesterol-lowering drug, has been shown in murine models to suppress lipoprotein-A{beta} secretion, concomitant with maintaining blood-brain-barrier function and suppressing neurovascular inflammation. Probucol has also been shown to protect cognitive function in dietary-induced amyloidogenic mice. This protocol details the Probucol in Alzheimers Study (PIA-study), a double-blind, randomised, placebo-controlled drug intervention trial investigating if Probucol attenuates cognitive decline in patients with mild-to-moderate AD. Objectives: The primary objective of the 104-week study is to assess whether Probucol supports cognitive function and delays brain atrophy in AD patients. A secondary objective is to determine whether Probucol treatment will reduce cerebral amyloid burden.


Background and rationale
Alzheimer's disease (AD) is a neurodegenerative disorder affecting approximately 50 million people worldwide. Extracellular deposition of amyloid beta (Aβ) is a hallmark pathological feature of AD featuring prominently within the hippocampal formation and entorhinal cortex.
Amyloidosis is positively associated with cognitive decline in AD and targeting amyloidosis presently is a therapeutic priority 1 . Recently, the US Food and Drug Administration (FDA) Federal Drug Agency approved Aducanumab, a treatment which decreases amyloid plaque burden in some patients with AD 2, 3 .
Microvascular disturbances are the first pathological feature of AD that may include microbleeds; hypo-perfusion and or blood-brain barrier dysfunction with changes in the extracellular matrices associated with astrogliosis 4,5 . Contemporary treatments for AD include cholinesterase inhibitors such as Galantamine, Rivastigmine, or Donepezil, to support synaptic activity, or Memantine to regulate glutamate 6 . Remarkably, of approximately 400 clinical trials in AD, to our knowledge, none to date have targeted the brain microvasculature, or peripheral metabolism of Aβ to reduce risk for, or progression of AD.
Several recent epidemiological studies show that systemic measures of Aβ in blood positively correlate with cerebral amyloid burden and cognitive decline in AD 7,8 . A causal association is suggested by findings that plasma Aβ isoforms discriminate with a high degree of accuracy in individuals who go on to develop AD, decades before onset of disease 8 . However, presently the mechanism(s) by which peripheral Aβ metabolism might exacerbate AD risk are not well understood. Insight into how blood Aβ increases risk for AD comes from findings that in humans, greater than 90% of blood Aβ 1-40 and 97% of the particularly proamyloidogenic Aβ 1-42 is associated with plasma lipoproteins 9 , principally the triglyceride-rich lipoproteins (TRL) of hepatically derived very-low-density-lipoproteins (VLDL) and of postprandial chylomicrons 10 . To directly address the hypothesis of a lipoprotein-Aβ/capillary axis for AD, mice were engineered to synthesise human Aß restricted exclusively to the liver.
Lam et al. reported marked neurodegeneration concomitant with capillary dysfunction, parenchymal extravasation of lipoprotein-Aß, and neurovascular inflammation 11 . The liverspecific amyloid mice also showed impaired performance in the passive avoidance test, suggesting impairment in hippocampal-dependent learning. Collectively, these findings provide a strong rationale to consider interventions that target and modulate peripheral metabolism of lipoprotein-Aβ to mitigate AD risk.
Probucol is an historic and safe cholesterol lowering drug, clinically used in Japan since 1985, with potent anti-inflammatory and anti-oxidant properties [12][13][14] . Probucol was also shown to profoundly attenuate dietary induced synthesis and secretion of lipoprotein-Aβ 15,16 concomitant with cerebral capillary integrity sparing 17 . In a dietary-induced diabetic murine model, Probucol was also found to support hippocampal-dependent memory recall 18 . The pleiotropic properties of Probucol and significant clinical use experience justifies considering repurposing Probucol to test efficacy in supporting cognitive function in patients with AD.
We describe the Probucol in Alzheimer's-study (PIA-Study). The study is a phase II placebocontrolled, double-blind clinical trial assessing the efficacy of Probucol in AD. Key outcome measures include cognitive function, regional volumetric changes in brain and cerebral amyloid load.

OBJECTIVES
The primary objective of this study is to evaluate the efficacy of Probucol (Lorelco™) on cognitive performance in AD patients over a 104-week treatment period. The secondary objectives are [1] to evaluate regional volumetric changes and cerebral amyloid abundance in the brain of AD patients treated with Probucol (Lorelco™) over a 104-week treatment period, [2] to evaluate improvement or maintenance of quality-of-life parameters in patients with AD, and [3] to assess the safety and tolerability of Probucol (Lorelco™) in patients with AD.

Trial design
This is a single-site, phase II, randomised, double blind, placebo-controlled parallel group study in adults with mild-to-moderate AD. The study will assess the efficacy, safety and tolerability of the treatment of AD individuals with Lorelco™. Participants, study doctors and researchers will be blinded to allocation of the study medication. The maximum study duration is 112 weeks (2 years, 8 weeks), with a treatment period of 104 weeks. There is a 4-week screening phase to ensure all participants have measurable mild or moderate AD and to ensure eligibility in the study. There is also a 4-week follow-up after the end of the treatment 6 period. We aim to recruit 300 participants for this study. Eligible participants will be randomised in a 1:1 (active: placebo) ratio using permuted block randomisation. Eligible participants will be randomised to a unique participant code, which will be assigned to a participant number. Participant numbers will be randomised to either Probucol (Lorelco™) or placebo manufactured by Oxford Compounding. The trial coordinator will randomly assign the participant's screening number to a unique participant code at Week 1, Day 1.
Participants will be dosed as follows; week 1 and 2: 1 x placebo taken in the morning, with food; week 3: 1 x 250 mg Lorelco™ (or matching placebo) taken in the morning, with food; and week 4 -104: 1 x 250 mg Lorelco™ (or matching placebo) taken in the morning and in the evening, with food. An overview of the study design is shown in Figure 1 and the overall schedule of the trial is illustrated in Table 3.

Study setting and recruitment
This study will be based in Australia. All assessments and blood collection will be completed at the Australian Alzheimer's Research Foundation (AARF) based at Hollywood Specialist Centre, Nedlands, Western Australia. Positron Emission Tomography (PET) imaging will be completed at Sir Charles Gairdner Hospital, Nedlands, Western Australia. Magnetic Resonance Imaging (MRI) will be completed at Envision Medical Imaging, Perth, Western Australia. To reach the targeted sample size, participants will be identified and recruited from the investigators' private and public patient clinics; referrals from GP or other specialists; phone calls to site via word of mouth; the Alzheimer's Association Research Foundation website; or via database review where participants who have previously given permission for the site to contact them to inform them with new studies. Participants will also be recruited through advertising and editorials on social, print, radio and/or television media; correspondence and promotions via not-for-profit organisations and research partners; website and newsletter content.

Eligibility criteria
Individuals will be eligible for the study if they meet all of the inclusion criteria and do not satisfy any of the exclusion criteria listed in Table 1. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint  T  /  M  R  I  I  m  a  g  i  n  g  O  n  s  i  t  e  v  i  s  i  t   1  -1  .  5  h  o  u  r  s   S  a  f  e  t  y  E  v  a  l  u  a  t  i  o  n  ,  p  h  y  s  i  c  a  l  ,  a  n  d  n  e  u  r  o  l  o  g  i  c  a  l  a  s  s  e  s  s  m  e  n  8. Normal coagulation laboratory assessments at screening. 9. Lipids (total cholesterol, HDL and LDL) must be within < 1.5 x the upper limit of normal for the local laboratory reference range at the screening visit. 10. FBC must be within < 1.5 x the upper limit of normal for the local laboratory reference range at the screening visit. 11. Pregnancy: a. Must be of non-childbearing potential (i.e., surgically sterilised [hysterectomy, bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before the screening visit]) or postmenopausal (where postmenopausal is defined as no menses for 12 months without an alternative medical cause), or b. If of childbearing potential, must agree not to donate ova, not to attempt to become pregnant and, if engaging in sexual intercourse with a male partner, must agree to the use of acceptable forms of highly effective contraception from the time of signing the consent form until at least 30 days after the last dose of the study drug. 12. Estimated life expectancy of at least 2 years, in the opinion of the investigator. 13. A study partner (partner/spouse/carer) consents to the minimum requirements: a. will attend at least one screening visit b. will be available via phone or in person to provide information to the study as required.
chemotherapy. 8. Significant head injury within 5 years. 9. Electrolyte imbalance (e.g., on high steroids, pituitary tumours, and Addison disease). 10. Hypokalaemia, hypomagnesaemia and hypocalcaemia. 11. Other neurologic or psychiatric diagnosis that in the opinion of the investigator could interfere with cognitive function. 12. Major surgery is planned during the conduct of the trial, or a clinical event has occurred in the six months preceding study inclusion that may compromise ability to participate for the duration of the study. 13. Evidence of stroke. 14. Current diagnosis with a psychiatric disorder, or taking psychotropic medications. 15. Other excluded medications will be those that are; • Specifically contraindicated with Probucol, based on historic clinical indications for the treatment of cardiovascular disease. Stable use (for at least 3 months) of cholinesterase inhibitors and memantine will be allowed.

Intervention description
During the initial recruitment and screening phase, patients will be screened against the exclusion criteria to ensure suitability for participation. During the screening phase, participants will undergo a short cognitive screening assessment, safety assessment, and complete a PET scan to determine cerebral amyloid load. Study medication will commence with a single dose escalation design with all participants receiving initially for two-weeks 1 X placebo consumed with food, after which baseline measures for cognitive performance, structural and functional brain MRI scans will be completed. will contact the patient or caregiver by phone record to determine any adverse events.

Supply of study drug
Probucol used in this study will be commercially available tablets, Lorelco™, produced by Aventis Pharmaceuticals and wholesaled by Otsuka Pharmaceutical Co., Ltd. Lorelco™ tablets (250 mg) will be over-encapsulated inside an opaque capsule shell and backfilled with microcrystalline cellulose. Individual doses of Lorelco™ will be dispensed by the site pharmacy. Matching placebo opaque capsules with no active ingredients and a filler of microcrystalline cellulose will be compounded by Oxford Compounding.

Safety
Protocol violations should not lead to treatment discontinuation unless they pose a significant risk to participant safety. Trial stopping criteria, dose stopping rules and individual dosage adjustments are indicated in Table 2.

Adverse events
The investigators will report any serious adverse events (AEs) occurring during the clinical trial, independent of direct causal relationship with the treatment, within 24 hours.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 21, 2021. ; Unblinding will be permissible in the event information is required to ensure the participants safety in case of an AE. The study doctor will provide Oxford Compounding with the unique participant code to unblind the participant. All AEs will be reviewed by the independent DSMB, specifically appointed for the trial. Table 2. Criteria PIA trial stopping criteria and intervention dosage adjustments Trial stopping criteria o Substantial deviations from the approved protocol o Adverse-effects of unexpected type, severity, or frequency are encountered o As the trial progresses, the continuation of the trial would disadvantage some of the participants as determined by the investigator group, trial monitors or the data safety and monitoring committee (DSMB). *All participants will take part in a safety evaluation 4 weeks following discontinuation.

Dose stopping criteria and individual dosage adjustments
Dosing may be stopped or modified if suspected adverse drug reactions, changes in vital signs, ECGs, or clinical laboratory results are observed, and these changes pose a significant health risk. Of particular note for dose discontinuation are the following criteria; o Corrected QT/QTc interval is in excess of 500 ms, or if it increases > 50 ms compared to baseline (baseline will be calculated as the mean of two time points, screening and baseline day 1). o Occurrence of QT/QTc interval prolongation in association with symptoms of arrhythmia o Subsequent prescription of a drug with potential QTc prolongation (Antimalarial; Macrolides; Quinolones; Triazole antifungals; Anti-arrhythmic; Antiemetic; Antidepressant; Antipsychotics) o Evidence of liver dysfunction, or primary biliary cirrhosis o If for any reason the investigator team determines that continued participation in the trial is not in the participant's best interest.

Participant Withdrawal
If a participant decides to withdraw from the project, participants are asked to notify a member of the research team. If a participant withdraws consent during the research project, the study doctor and relevant project team members will not collect additional personal information from the participant. However, personal information already collected will be retained to ensure that the results of the research project can be measured properly and to comply with law. Participants will be made aware that data collected by the Sponsor up to the time the participant withdraws will form part of the research project results.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 21, 2021. ;

Adherence
The two-week placebo period will serve to monitor participant adherence to the treatment schedule. Participants will also be required to return the study treatment webster packs at every clinic visit. In the event adherence falls below 80%, participants will be re-trained in the administration of the study medication. If adherence continues to be below 80% the participant will be withdrawn from the study.

Concomitant care
This study allows for 'usual clinical care'. Some medications or treatments may not be permitted during participation in this study. The study doctor will collect information about concomitant medication use during every study visit and safety screening. Participants will not be permitted to take part in other studies/investigational treatments for AD or other health conditions while taking part in this study.

Study Procedures
For the exact timing of each procedure, please refer to the Schedule of Assessments (SoA; Table 3).
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 21, 2021. ; It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
(which was not certified by peer review)

Informed Consent
The Information and Informed Consent Form (ICF) will be provided to patients at Screening and signed consent must be provided prior to any study procedures being performed.

Medical History
A full medical history will be obtained at screening, including a detailed neurologic history, other medical and surgical history, medication history and drug allergies. Demographic data including gender, ethnicity, and race will be recorded.

Height and Weight
Body height (centimetres) and weight (kilograms) will be measured, and body mass index (BMI) will be calculated.

Pregnancy Test
Female patients (women of child-bearing potential (WOCBP) only) will complete a urine chorionic gonadotropin (hCG) pregnancy test at screening, baseline, and again at EoS visit.

Safety and Tolerability Assessments
Safety will be determined by evaluating physical and neurological examinations, vital signs, clinical laboratory parameters, 12-lead ECGs and AEs. Abnormal vital signs assessments, clinical laboratory safety tests, ECGs and physical examinations that are judged by the PI as clinically significant will be recorded as AEs or SAEs. The timing of all safety assessments is presented in Table 3.

Vital Signs
Vital signs assessments will include systolic and diastolic blood pressure, heart rate (HR), respiratory rate (RR) and body temperature. Patients should be resting in a supine position for at least 5 minutes prior to and during vital signs measurements.

Clinical Laboratory Safety Tests
Fasted blood samples (minimum 8 hour fast) will be collected by venepuncture at screening, baseline, weeks 3, 4, 5, 15, 26, 39, 52, 65, 78, 91 and 104 weeks (an estimated 13 mL of blood will be collected per visit and a total of 160 mL will be collected over the 2-year . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 21, 2021. ; study).
Blood samples for haematology, serum biochemistry (including liver function tests) will be collected at selected time points throughout the study (see Table 3). Test results will be monitored for potential AEs, including gastrointestinal bleeding (haemoglobin) and rhabdomyolysis (plasma CK). Apolipoprotein E genotype will also be determined.

Electrocardiogram
Twelve-lead ECGs will be assessed (including but not limited to the measurements of ventricular HR, PR interval, RR interval, QRS duration, QT interval and QTcF). Screening and prior to first dose, triplicate 12-lead ECGs (collected within 5 minutes with each reading separated by at least 1 minute) will be taken to establish eligibility at baseline. Triplicate ECGs will also be recorded at the EoS visit. The average value for the triplicate will be utilised for assessing QTcF inclusion criteria. All other ECGs will be single readings.

Physical Examination
A full physical examination will be performed at screening and at the EoS visit. The full physical examination will include, at a minimum, assessment of the following systems: skin, head, ears, eyes, nose and throat, lymph nodes, heart, chest, abdomen and extremities, and a neurological examination (assessment of speech, cranial nerves, peripheral nerves, motor power, deep tendon reflexes, sensation, coordination and gait) and any other focussed assessments suggested by the presence of specific symptoms. All other scheduled assessments will be symptom-directed.

Free and Cued Selective Reminding Test (FCSRT) 19
The FCSRT assessment will be performed at screening only for eligibility determination. A cueing index of ≤ 0.79 is required for study entry. The FCSRT is a cued recall test that utilises a controlled encoding technique to ascertain that impairment in recall and cueing are due to a memory deficit rather than a failure of encoding.
Clinical dementia rating scale (CDR) 20 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.20.21266372 doi: medRxiv preprint The CDR provides two scores, a global score (GS) and a sum of boxes (SOB). The GS distinguishes a participant's level of impairment into the following categories: 0 (normal); 0.5 (questionable dementia; 1 (mild dementia); 2 (moderate dementia) and 3 (severe dementia).
The SOB is scored from 0 -18 with higher scores indicating a greater level of impairment.
The scale covers six domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care.

Mini Mental State Examination (MMSE) 21
The MMSE is a brief, widely used 30-item assessment of global cognition examining orientation, registration, calculation, recall, attention and language. The spelling of WORLD backwards will not be used in this protocol. Participants who score <22 at screening will be ineligible for study entry. MMSE will be assessed at screening and EoS.
All cognitive assessments will be performed by an independent assessor who will be blinded to treatment allocation.

Primary Outcome measures
The primary outcome measure will be the change in the Alzheimer's Disease Assessment An additional outcome measure will be assessment of brain morphometry and volume determined via magnetic resonance imaging (MRI) at baseline (pre-intervention) and EoS.
The MRI protocol will include the acquisition of 3 sets of data [1] Volumetric isotropic T1 scan (6.5 min). This will allow voxel wise segmentation and volumetric analyses (e.g., grey matter volume) to assess volume changes in characteristic locations which can yield diagnostic accuracy on approximately 90% 23 . Mesial temporal lobe (hippocampus and entorhinal cortex via Scheltens grading), global cortical atrophy (Pasquier scale) and parietal atrophy (Koedam score) as well as inferior lateral ventricle size will be assessed. Brain . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.20.21266372 doi: medRxiv preprint volume indices indicate that patients with AD have accelerated rates of brain volume loss of up to 4.5% per year compared to normal controls (1%). [2] 3D FLAIR scan (3.5min). This will demonstrate the small vessel ischaemic lesion load which will be scored according to the Fazekas method 24 . [3] Susceptibility weighted imaging (SWI) -a means of measuring micro bleed load and indicator of amyloid angiopathy and for the purposes of Quantitative Susceptibility Mapping (QSM) (~7 mins) 24 . This method quantitates regional brain iron content which is altered in AD compared with normal controls. Mesial temporal, basal ganglia, cingulate, cortical region of interest comparisons will be performed at baseline and at treatment completion. Visible micro bleeds on the SWI imaging will be graded using the Brain Observer Micro-Bleed Scale (BOMBS).

Secondary Outcomes
Quality of life will be assessed as a secondary outcome measure via the Alzheimer's Disease Cerebral amyloid load will be assessed as an additional imaging outcome measure. Brain amyloid imaging will be done with amyloid tracer positron emission tomography (PET) scans at baseline and at EoS. Dynamic and static PET imaging will be acquired. Analysis will include [1] visual assessment of amyloid load [2] quantitative assessment of amyloid burden, including standard uptake value ratio (SUVr) and, [3] dynamic imaging for blood perfusion measures.

Estimated sample size and power
Estimated sample sizes are calculated for the two primary outcome measurements: ADAS-Cog and grey matter atrophy (hippocampal). In order to ensure that the study has sufficient power to detect differences in both of the primary outcomes, the sample size chosen is the . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review) preprint
The copyright holder for this this version posted November 21, 2021. ; maximum of that calculated for each primary outcome.
The primary analysis is an intention-to-treat analysis and will include all randomized participants. Data will be analysed using both Generalised Estimating Equations (GEE) and Bayesian Analysis. The analysis of primary endpoints will use linear mixed-effects models, with random slopes and intercepts. For the ADAS-Cog, using mixed model analysis published estimates from the ADNI cohort 27 suggest a sample size of 125 AD participants per trial arm (total N = 250) will be required for power at 0.8 to detect a drug effect of 25% over two years and assuming a decline from baseline of 1.10 standardised units on the composite (SD change = 0.83). For the MRI markers, Ledig et al. reported the sample sizes required for a 25% intervention reduction over two years based on 322 patients with AD (with 117 followed for 24 months) and a reduction of 10.2% (6.2) for hippocampus 28 . Sample size calculations based on hippocampal volume suggest that 93 participants per treatment arm are required (total N = 186). Assuming a 20% attrition rate, a sample of 314 individuals will be recruited for the cognitive study, and 233 individuals will be randomly chosen for the imaging study.

Outcomes
The primary analysis is an intention-to-treat analysis of all randomized participants. Data will be analysed using both GEE and Bayesian Analysis. The analysis of primary endpoints will use linear mixed-effects models, with random slopes and intercepts. Analysis of all primary and secondary endpoints contrasting Probucol and placebo, after adjusting for covariates, will use mixed effects-regression with 'random' intercepts and slopes (as has been used for power calculations). Mean differences and associated 95% confidence intervals will be presented for the 'fixed' effect of Probucol treatment. No formal interim analyses are planned at this time.

Additional analyses
Further analysis investigating the relationship between change scores (post-minus preintervention scores) for the primary ADAS-Cog with MRI volumes (total grey matter, hippocampus, and medial temporal lobe volumes) and specific blood biomarkers (e.g.: plasma lipoprotein-Aβ) will be considered using Pearson (or Spearman where appropriate) correlation analysis. For all other correlations between recorded variables that lack an a priori . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review) preprint
The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.20.21266372 doi: medRxiv preprint hypothesis, control of statistical errors will be carried out using Holm-Sidak corrections for multiple comparisons.
If Probucol treatment is successful, a directed acyclic graph Bayesian network analysis will be carried out a posteriori on variables identified to be significant predictors of either grey matter arrest or neuropsychological performance to better elucidate mechanisms of the effect of Probucol. Greedy equivalence search will be used to identify statistical conditional dependencies between variables and directionality will be estimated using the linear, non-Gaussian, acyclic causal models (LiNGAM) approach 29, 30 . Goodness of fit will be estimated using a χ 2 test contrasting the identified model against a saturated model.
In addition to Bayesian analyses, the traditional General Linear Model analysis will also be utilised to compare Probucol to placebo, after adjusting for covariates. The Generalized Estimating Equations method, which extends the generalized linear model to allow for analysis of repeated measurements or other correlated observations, will also be utilised.
Missing data on the ADAS-Cog will not require data imputation. The scoring methodology for the ADAS-Cog as proposed by Verma et al. will be utilised as it estimates cognitive impairment using the set of items answered by the patients 22 . Any additional missing data will be identified using Missing Values Analysis and will be replaced using multiple imputation where appropriate. Mean difference and associated 95% confidence intervals will be presented. Data will be analysed using Stata Version 16.

Data management
Data will be collected by study delegated personnel on paper source maintained in a participant study binder in secure facilities at Alzheimer's Association Research Foundation (AARF). Identifiable data will be stored securely and kept in a locked cabinet with access restricted to the investigator team, site and monitoring personnel. All other data will be deidentified to sure confidentiality of participant data. Data will be stored electronically on password protected web-enabled clinical trial data electronic management system (REDCap) located in an ISO27001 compliant facility at Curtin University. Clinical records collected at recruitment will be kept in a locked cabinet in a locked office at the site and will collectively be housed in secure facilities at the AARF. Participants' study information will not be . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review) preprint
The copyright holder for this this version posted November 21, 2021. ; released outside of the study without the written permission of the participant. All data will be securely archived as per the Sponsor's data policy for a minimum of 25 years.

Trial monitoring and formal committees
The trial monitoring committee (TMC), comprised of the principal investigator, key trial staff including the trial manager, a nurse representative and a consumer representative, are responsible for trial setup, ongoing management and promotion of the trial. The trial steering committee (TSC), comprising the investigator team including geriatricians, cardiologists, neuroradiologists, nuclear medicine physicians, neuropsychologists, a biostatistician, clinical biochemists, consumer and community representatives, will provide overall supervision of the study and are responsible for interpretation and dissemination of results.
AARF employs independent data auditors who will monitor and audit compliance of data entry/management, legislation, regulations, guidelines and codes of practice, at quarterly intervals. Findings from each audit will be discussed with the study coordinator and thereafter with the investigator team to ensure any action items are addressed promptly and appropriately.
An independent data safety and monitoring committee (DSMB) will oversee the safety aspects of the study. The DSMB consists of members with expertise in clinical pharmacology, biostatistics, clinical trial design, and clinical cardiology. Members of the DSMB will not be investigators of the study nor will they have any conflict of interest with the investigators. The committee will meet periodically to advise the TSC on the progress of efficacy and safety data as it accumulates throughout the course of the study. The TSC and DSMB will provide independent oversight of the study.

Ethics Approval
The PIA study has been approved by Bellberry Ltd Human Research Ethics Committee personnel and relevant committees.

Informed consent and withdrawal from the study
Participants will be in the mild stages of dementia and therefore are expected to be able to provide informed consent. An investigator or research staff delegate will explain all study procedures and possible risks to the participant. The participant and their nominated study partner will have an opportunity to have all questions answered and thereafter will sign and date the ICF, indicating willingness to participate in the study. Participants will be informed prior to consent that they can withdraw at any time without their care being affected in any way.

Dissemination
Participants will be updated about the progress and results of the study via presentations or newsletters from the investigator group. The results will be disseminated via peer-reviewed publications, key conferences and local stakeholder events.

Trial Status
This study is in the process of recruiting participants and expected to complete in 2026.

Patient and public involvement
The study was developed in consultation with a consumer advocate representing the Consumer and Community Involvement Program (https://cciprogram.org/). The trial will be overseen by the trial steering committee (TSC), including patient and public members.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

COMPETING INTERESTS
None declared.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  I freely agree to participate in this study as described and understand that I am free to withdraw at any time during the study without affecting my future health care. • I understand the purposes, procedures and risks of the research described in this Participant Information Sheet. Although I understand that the purpose of this study is to improve the quality of medical care, it has also been explained to me that my involvement may not be of any direct benefit to me. • I understand that access may be required to my medical records for the purpose of this study as well as for quality assurance, auditing and in the event of a serious adverse event. I understand that such information will remain confidential. • I understand that I will be randomised to either the Probucol (Lorelco™) or Placebo group, and that neither I nor the Study Doctor will know which group I am in.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  D  e  c  l  a  r  a  t  i  o  n  b  y  t  r  i  a  l  d  o  c  t  o  r   I  h  a  v  e  g  i  v  e  n  a  v  e  r  b  a  l  e  x  p  l  a  n  a  t  i  o  n  o  f  t  h  e  c  l  i  n  i  c  a  l  t  r  i  a  l  ,  i  t  s  p  r  o  c  e  d  u  r  e  s  a  n  d  r  i  s  k  s  a  n  d  I  b  e  l  i  e  v  e  t  h  a  t  t  h  e  p  a  r  t  i  c  i  p  a  n  t  h  a  s  u  n  d  e  r  s  t  o  o  d  t  h  a  t  e  x  p  l  a  n  a  t  i  o n .

Appendix B
Consent Form for Continued Participation in the Event of Cognitive Decline  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.20.21266372 doi: medRxiv preprint a  m  e  o  f  S  t  u  d  y  D  o  c  t  o  r  (  p  l  e  a  s  e  p  r  i  n  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 21, 2021. ; N  a  m  e  o  f  p  a  r  t  i  c  i  p  a  n  t  (  p  l  e  a  s  e  p  r  i  n  t  )  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  F  i  r  s  t  N  a  m  e  ,  M  i  d  d  l  e  N  a  m  e  o  r  I  n  i  t  i  a  l  ,  L  a  s  t  N  a  m  e   D  e  c  l  a  r  a  t  i  o  n  b  y  S  t  u  d  y  D  o  c  t  o  r   I  h  a  v  e  g  i  v  e  n  a  v  e  r  b  a  l  e  x  p  l  a  n  a  t  i  o  n  o  f  t  h  e  s  t  u  d  y  ,  i  t  s  p  r  o  c  e  d  u  r  e  s  a  n  d  r  i  s  k  s  a  n  d  I  b  e  l  i  e  v  e  t  h  a  t  t  h  e  p  a  r  t  i  c  i  p  a  n  t  h  a  s  u  n  d  e  r  s  t  o  o  d  t  h a t e x p l a n a t i o n .

Declaration by study partner
• I have read, or have had read to me, and I understand the General Information PICF as well as this Partner Information Sheet and Consent Form. • I agree to the above requirement of study partners, as set out in the Participant Information sheet and Consent form. I also acknowledge that at no time am I, as the study partner, receiving the treatment. • I have had an opportunity to ask questions and I am satisfied with the answers I have received.
• I freely agree to participate in this study as described and understand that I am free to withdraw at any time during the study without affecting my future health care. • I freely agree to meet the minimum study requirements which includes; attending one screening visit, completing a questionnaire at the start, at 6 months, and at the end of the study, and be available by phone monthly, as needed. • I understand that by consenting to the minimum study requirements, the study participant may continue through the screening phase of the study and, if eligible, will receive the study medication. • I understand that I will be given a signed copy of this document to keep. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.20.21266372 doi: medRxiv preprint  S  i  g  n  a  t  u  r  e  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  _  D  a  t  e  _  _  _  _  _  _  _  _  _  _  _  T  i  m  e  _  _  _  _  _  _  _  _  _  _  _   N  a  m  e  o  f  t  r  i  a  l  d  o  c  t  o  r  (  p  l  e  a  s  e  p  r  i  n . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 21, 2021. ;